Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2016
2016
www.reviral.co.uk ReViral is a UK-based biotechnology company with a portfolio of drugs to treat RSV infection. The most advanced programme, RV521, is a highly potent fusion inhibitor. RV521 has received top-line safety and pharmacokinetic data for Phase 1 single and multiple ascending dose (SAD and MAD) trials RV521 is delivered by a convenient oral dose and is now in Phase 2a trial to provide clinical POC. In September 2015, ReViral announced the successful completion of a US $21 million Series A financing led by Edmond de Rothschild Investment Partners and OrbiMed with additional new investment from Brace Pharma Capital.
2019
2019
www.viriom.com Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to the best antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV and viral hepatitis.
2018
2018
2018
2018
www.enyopharma.com ENYO Pharma has built a unique drug discovery engine based on mimetism of the secular strategy how viruses have adapted during evolution to hijack the human cellular functions for their own benefit. The company has developed an exhaustive database of all known virus/human protein-protein interactions from which new cellular targets are discovered. From that, small active molecules are designed and developed until Phase II clinical trials internally or through partnerships. The company is currently developing treatments against liver diseases and infectious diseases.
2017
2017
www.kandytherapeutics.com Launched in 2017, KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions. KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus and is led by an experienced management team and backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
2017
2017
2017
www.nerretherapeutics.com NeRRe Therapeutics is a clinical-stage company developing a unique pipeline of three neurokinin(NK)-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity associated with neurokinin-1 receptor system dysfunction. The portfolio is tackling a range of disorders with high unmet need including chronic refractory cough and chronic pruritus. NeRRe Therapeutics is backed by international life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed, all of whom took part in a £23m Series B fundraising in 2017. The company was founded in 2012 as a spin out from GSK, which transferred its NK antagonist portfolio, including clinical data, toxicity, safety and formulation packages, and all associated intellectual property to NeRRe.
2016
www.iovance.com NASDAQ: IOVA Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported to have achieved objective and complete response criteria, respectively. Iovance's lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer, the company's TIL therapy technology is potentially applicable to ovarian, breast, bladder, colorectal and other cancers. In September 2017 the Company announced the closing of its initial public offering of 8,846,154 shares of common stock at a public offering price of $6.50 per share, before underwriting discounts. The gross proceeds from the offering were approximately $57.5 million.
2016
2016
www.kyntherapeutics.com Kyn Therapeutics was founded by professor George Georgiou, Ph.D. at the University of Texas, Austin and funded in March 2016 by OrbiMed and Atlas Venture. Kyn is building a leading immune-oncology company with the primary program focused on the clinically validated IDO/TDO immunosuppressive pathway. IDO and TDO are metabolic enzymes overexpressed in many cancers that convert tryptophan to kynurenine. Kynurenine accumulates in the tumor microenvironment where it enters immune cells and binds the aryl hydrocarbon receptor triggering broad immunosuppression. Kynurenine signaling affects multiple cell types in the innate and adaptive immune system and inhibiting this pathway unleashes the immune system to attack the tumor. Kyn Therapeutics is developing a novel approach to target both IDO and TDO mediated immunosuppression through enzymatic degradation of kynurenine systemically and in the tumor microenvironment. This approach is differentiated from the current inhibitors in the clinic that only target IDO expressing tumors. Inhibiting the IDO/TDO pathway is expected to have broad application across many tumor types.
2016
2016
www.orbimed.com From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed scouts the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. The company has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Orbimed's team of distinguished scientific, medical, investment and other professionals manage approximately $13 billion across public and private company investments worldwide.